1. The star target in SLE: IL-17.
- Author
-
Yang, Yi, Yan, Chen, Yu, Le, Zhang, Xiuling, Shang, Jingjing, Fan, Jie, Zhang, Rongwei, Ren, Jie, and Duan, Xinwang
- Subjects
- *
INTERLEUKIN-17 , *SYSTEMIC lupus erythematosus , *IMMUNOLOGICAL tolerance , *T cells , *B cells - Abstract
Purpose: The purpose of this review is to discuss the significance of IL-17 in SLE and the potential of IL-17-targeted therapy. Background: Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect many organs and tissues throughout the body. It is characterized by overactive B and T cells and loss of immune tolerance to autoantigens. Interleukin-17 (IL-17) is a cytokine that promotes inflammation and has been implicated in the pathogenesis of several autoimmune diseases as well as inflammatory diseases. In in vitro cellular experiments in lupus susceptible mice or SLE patients, there is substantial evidence that IL-17 is a highly promising therapeutic target. Methods: We searched papers from PubMed database using the search terms, such as interleukin-17, systemic lupus erythematosus, treatment targets, T cells, lupus nephritis, and other relevant terms. Results: We discuss in this paper the molecular mechanisms of IL-17 expression, Th17 cell proliferation, and the relationship between IL-17 and Th17. The significance of IL-17 in SLE and the potential of IL-17-targeted therapy are further discussed in detail. Conclusion: IL-17 has a very high potential for the development as a star target in SLE. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF